Thrifty,

I sold my positions in both humanigen and relief. Both show potential in quelling excesssive immune response. I was in humanigen for treatment of car-t immune over response and was intrigued by avaptadil for potential for asthmatics in response to viral infection.

Every criticism/concern about Cytodyn business management/acumen can be made tenfold, IMO about humanigen and relief.



More than that, their therapeutics, while likely effective in relatively narrow applications, do not hold a candle to leronlimab.

I’m as greedy and impatient as many, but I continue to read extensively about leronlimab, RANTES and the intersection of innate and acquired immune systems.

We may be wrong, but I believe Leronlimab and very targeted immune modulation will transform medicine.

Rubraqiercus could not possibly have need more correct in noting that inflammation is a very big deal. Reducing this inflammation, in a specific way without resorting to immunosuppressive steroids, will be the future of a large part of medicine.

I have invested accordingly, which does not include humanigen or relief therapeutics.

Hope that helps.